The FDA approved Boehringer's nerandomilast, now Jascayd, as the first new U.S. treatment for idiopathic pulmonary fibrosis ...

Nerandomilast appears to reduce the risk of death in people with IPF and PPF, according to analyses of clinical trial data.

In her columns debut, Debbie Klein shares the story of her late husband Steve's idiopathic pulmonary fibrosis diagnosis.

Columnist Sam Kirton's diagnostic journey was relatively short compared with that of other idiopathic pulmonary fibrosis (IPF) patients.

LTI-03 was shown to reduce inflammation and scarring in lung tissue collected from IPF patients and analyzed in a lab, ...

For pulmonary fibrosis patients, lung transplant is often the best choice for extending life and improving quality of life. Because PF is a progressive disease with no current cure, the lungs ...

A Phase 3 clinical trial testing Boehringer Ingelheim’s oral investigational treatment nerandomilast in people with idiopathic pulmonary fibrosis (IPF) has met its primary goal of demonstrating the ...

Researchers have developed an inhalable prototype medicine that may be able to repair lung scarring caused by idiopathic pulmonary fibrosis (IPF) by stimulating the growth of stem cells directly in ...

An experimental oral therapy for idiopathic pulmonary fibrosis (IPF) has been tolerated well in an ongoing Phase 2 clinical trial, according to interim data announced by its developer GRI Bio. “We are ...

Families will gather this week to celebrate Thanksgiving here in the U.S. But how do you safely navigate a large family gathering when colds, the flu, and COVID-19 are all circulating? After I ...

The U.S. Food and Drug Administration (FDA) has granted its orphan drug designation to Alentis Therapeutics’ antibody-based therapy lixudebart (ALE.F02) for idiopathic pulmonary fibrosis (IPF). Orphan ...